Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daytrana in Children with Autism and ADHD
NCT00541346Phase 3Completed
- Sponsor
- University of Oklahoma
- Start
- Sep 2007
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by University of Oklahoma. Primary endpoint: Attention Deficit Hyperactivity Disorder Rating Scale - IV Total Score at 8 weeks. Started Sep 2007; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00541346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541346.